Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462826 · ClinicalTrials.gov registry record · Phase 2
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00462826: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00462826 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00462826, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer. VEGF Trap may stop the growth of endometrial cancer by blocking blood flow to the tumor and by carrying tumor-killing substances directly to endometrial cancer cells.
Interventions
- BIOLOGICAL ziv-aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462826
The ClinicalTrials.gov registry entry for NCT00462826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ziv-aflibercept is the first listed.
NCT00462826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462826 about?
NCT00462826 is a clinical study titled "VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer". This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer. VEGF Trap may stop the growth of endometrial cancer by blocking blood flow to the tumor and by carrying tumor-killing substances directly to endometrial...
What is the current status of trial NCT00462826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2007-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00462826?
The interventions under investigation include: ziv-aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00462826?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.